Immunovant, Inc. (IMVT) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
IMVT Revenue Analysis (2018–2025)
As of February 28, 2026, Immunovant, Inc. (IMVT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2026) recorded $0 in revenue.
Looking at the longer-term picture, IMVT's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY). Compare IMVT vs ARGX →
Peer Comparison
Compare IMVT's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IMVTCurrent | $0 | - | - | - | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-438,152,000 | - |
| 2024 | $0 | - | $0 | - | $-270,209,000 | - |
| 2023 | $0 | - | $0 | - | $-208,276,000 | - |
| 2022 | $0 | - | $0 | - | $-156,033,000 | - |
| 2021 | $0 | - | $0 | - | $-108,117,000 | - |
| 2020 | $0 | - | $-21,000 | - | $-59,678,000 | - |
| 2019 | $0 | - | $0 | - | $-450 | - |
| 2018 | $0 | - | $0 | - | $-136,740,000 | - |
See IMVT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMVT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare IMVT vs AGIO
See how IMVT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is IMVT's revenue growth accelerating or slowing?
IMVT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is IMVT's long-term revenue growth rate?
Immunovant, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is IMVT's revenue distributed by segment?
IMVT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.